Q. The FLAURA study compared first-line osimertinib versus geftitinib or erlotinib and demonstrated
A. Improved response rates with osimertinib
B. Statistically nonsignificant improvement in PFS with osimertinib
C. Overall survival was the same
D. Osimertinib was associated with lower risk of adverse events
Answer: Osimertinib was associated with lower risk of adverse events
